Minority Access & Outcomes with Anti-BCMA CAR T Therapy in #Myeloma | Luca Paruzzo, MD | #ASH24

Minority Access & Outcomes with Anti-BCMA CAR T Therapy in #Myeloma | Luca Paruzzo, MD | #ASH24Подробнее

Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24Подробнее

The potentially curative role of CAR-T therapy in myelomaПодробнее

CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24Подробнее

Early Identification of Toxicity & Responses to BCMA CAR-T Therapy in RRMM | Kai Rejeski, MD |#ASH24Подробнее

Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman | #ASH24Подробнее

ASH 2024: Ziad Abuhelwa, MD on Patterns & Outcomes in Myeloma After Anti-BCMA CAR T TherapyПодробнее

Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24Подробнее

Clinical Trial: BCMA CAR T Cell Trial with Adam Cohen, MD, University PennsylvaniaПодробнее

Meta-analysis: anti-BCMA CAR-T in R/R multiple myelomaПодробнее

Phase 1 Study of Antio-cel an Anti-BCMA CAR-T for RRMM | Michael Bishop | #ASH24Подробнее

PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myelomaПодробнее

The future of anti-BCMA CAR T-cell therapy in myelomaПодробнее

CAR T-cell therapy treating myelomaПодробнее

Anti-BCMA CAR T-cell therapy for multiple myeloma: latest studiesПодробнее

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD | #ASH24Подробнее

Anti-BCMA CAR T-cell therapy in myeloma: updates from ASH 2020Подробнее

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory Multiple MyelomaПодробнее